LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue	$ (310,463)	$ (331,339)	$ (391,866)
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	91,000
License revenue recognized	3,000
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109,500
PAION AG | Cost Reimbursement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,300
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	1,400
Sales milestone payments receivable	20,000
License revenue recognized	$ 8,000
Royalties payable period after first commercial sale of product	10 years
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 2,400	$ 800
Percentage of reimbursed for direct and certain indirect manufacturing costs	110.00%
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Obligation to pay royalties	$ 2,500
Percentage of royalty payable on net sales	6.00%
Percentage of royalty on payments received from sublicensees	15.00%
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of license revenue	$ 1,200
Percentage of royalty payable on net sales	5.00%
Percentage of royalty on payments received from sublicensees	20.00%
Clinical development and regulatory milestones amount payable	$ 15,100
Percentage of minimum royalty rate	4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds	7.50%
Paratek Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales	2.25%
Claim Expiration Date	2023-10
AstraZeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Subscription agreement one-time milestone payment on net sales	$ 5,000
Term of the milestone payment on net sales	3 months
Subscription agreement one-time milestone payment on first commercial sale	$ 10,000
Term of the milestone payment on first commercial sale	2 years